3.86

2.66% 0.10

After Hours: 3.84 -0.02 -0.52%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $3.86, with a volume of 2.98M. It is up +2.66% in the last 24 hours and up +10.60% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635.

Previous Close:

$3.76

Open:

$3.77

24h Volume:

2.98M

Relative Volume:

0.81

Market Cap:

$1.17B

Revenue:

$75.13M

Net Income/Loss:

$-146.41M

P/E Ratio:

-7.8711

EPS:

-0.4904

Net Cash Flow:

$-174.43M

1W Performance:

+12.54%

1M Performance:

+10.60%

6M Performance:

-36.72%

1Y Performance:

+58.85%

1-Day Range:

$3.77

$3.90

1-Week Range:

$3.37

$3.90

52-Week Range:

$1.94

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	3.86	1.14B	75.13M	-146.41M	-174.43M	-0.4904
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

11:08 AM

Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout By Investing.com - Investing.com Canada

11:08 AM

11:00 AM

Truist reiterates Buy on AbCellera stock ahead of 2H26 data - Investing.com

11:00 AM

10:56 AM

Truist reiterates Buy on AbCellera stock ahead of 2H26 data By Investing.com - Investing.com Canada

10:56 AM

10:54 AM

Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout - Investing.com

10:54 AM

Apr 14, 2026

Biotech Penny Stocks Rally OABI ABCL PACB 2026 - Gotrade

Apr 14, 2026

Is Jones Trading’s New Coverage of AbCellera (ABCL) Reframing Its Clinical-Stage Platform Narrative? - Yahoo Finance

Apr 14, 2026

AbCellera Biologics (ABCL) Committed to Leverage Differentiated Technology for Drug Discovery - Insider Monkey

Apr 14, 2026

Apr 13, 2026

Is AbCellera Biologics Inc affected by consumer sentimentWall Street Watch & Free High Return Stock Watch Alerts - baoquankhu1.vn

Apr 13, 2026

Wall Street Bullish on AbCellera Biologics Inc. (ABCL), Here’s Why - MSN

Apr 13, 2026

Portfolio Recap: Is AbCellera Biologics Inc part of any ETFMarket Activity Summary & Precise Swing Trade Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Insider Sell: What hedge funds are buying AbCellera Biologics Inc2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn

Apr 11, 2026

AbCellera Biologics Inc (HAM:8QQ) Stock Price & 30 Year Financial Data - GuruFocus

Apr 11, 2026

Apr 10, 2026

AbCellera Biologics (ABCL): New 'Buy' Rating from Jones Trading | ABCL Stock News - GuruFocus

Apr 10, 2026

Jones Trading initiates coverage of AbCellera Biologics (ABCL) with buy recommendation - MSN

Apr 10, 2026

Apr 09, 2026

JonesTrading Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $11 - Moomoo

Apr 09, 2026

ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill

Apr 09, 2026

Apr 07, 2026

Aug Big Picture: What is AbCellera Biologics Incs P E ratio telling usTrade Ideas & Accurate Buy Signal Notifications - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Insider Stock Buying Reaches US$1.04m On AbCellera Biologics - Moomoo

Apr 06, 2026

Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $3.52 - Moomoo

Apr 06, 2026

Press Releases about AbCellera Biologics Inc.Common Shares (Nasdaq:ABCL) - FinancialContent

Apr 06, 2026

ABCL Technical Analysis | Trend, Signals & Chart Patterns | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill

Apr 06, 2026

Apr 05, 2026

What sparked AbCellera Biologics to soar over 9% after hours - MSN

Apr 05, 2026

Apr 03, 2026